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 Abstract (100-120 words) 
Inflammatory bowel diseases (IBD), consisting of ulcerative colitis (UC) and Crohn’s 
disease (CD), are chronic immune-mediated diseases of the gut. Here, the potential role 
of mast cells (MC) is discussed, mainly focusing on preclinical studies. MC can be 
activated by antigen-mediated crosslinking of immunoglobulin receptors, by free light 
chains of immunoglobulins, stress and ATP. Upon activation, MC release bioactive 
mediators, of which the serine proteases mMCP-6 and Prss31 were shown to be 
involved in the development of acute colitis. Inhibition of MCs by activation of the 
inhibitory receptor LIMR3 or inhibitors of proteases may therefore represent new 
therapeutic targets to treat IBD. Human data are however lacking. 
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Introduction 
Crohn’s disease (CD) [1] and ulcerative colitis (UC) [2] are the two main types of 
idiopathic chronic inflammatory disorders (IBD) of the gastrointestinal tract, both 
associated with a significant impact on the quality of life of the affected individuals. 
While CD can affect any part of the gut, albeit with a predilection for the terminal ileum, 
UC rather typically starts in the rectum and may extend all the way up to the caecal area. 
Despite extensive scientific effort, the exact underlying cause of IBD remains unclear. It 
is however becoming increasingly clear that a dysregulated mucosal response to the 
commensal gut flora is involved, in particular in genetically susceptible individuals. In 
UC, this immune response involves an atypical Th2 response mediated by non-classic 
natural killer T cells. In contrast, in Crohn’s disease, imbalance between predominantly 
Th1 or Th17 cells and naturally regulatory T cells is proposed to underlie the mucosal 
inflammation and associated damage. In the present review, the evidence, albeit scarce, 
supporting a potential contribution of mast cells will be summarized. Mast cells are 
particularly interesting as they are not only involved in the immediate and delayed 
defense against foreign antigens [3], but also release a mixture of mediators known to 
affect mucosal barrier function[4-6], thereby increasing the access of intraluminal 
antigens to the mucosal immune system.  
 
Mast cells: general aspects 
Mast cells arise from hematopoietic progenitors in the bone marrow that in contrast to 
most other immune cells only mature when they arrived at their final destination, i.e. all 
vascularized tissues but especially the skin and mucosal tissues. Typically, mast cells 
reside in the mucosa at anatomical sites directly exposed to the environment, such as 
the skin, the airways and the gastrointestinal tract, where they are ideally positioned to 
respond to foreign antigens that have crossed the epithelial barrier[6]. Their number 
can vary significantly depending on the tissue studied but also during infections or 
inflammation. Both in man and mice, two main types of mast cells can be identified, 
largely based on location and protease content. In mice, connective tissue mast cells and 
mucosal mast cells are distinguished. Connective tissue mast cells reside mainly around 
venules[7] and nerve fibers and in serosal cavities. Mucosal mast cells on the other hand 
are present in the mucosa of the gut and lung, but in low numbers[8]. In humans, mast 
cells are characterized by the proteases they contain: the MCT–type mast cells 
containing tryptase but little or no chymase, and the MCTC-type mast cells containing 
tryptase and chymase[9].  Almost all human mucosal mast cells are MCT while MCTC are 
typically located in the lamina propria and submucosa. 
Mast cells can be activated by a wide variety of stimuli. The most well known 
mechanism of activation is cross-linking of the high affinity IgE receptor FcRI. This 
receptor binds antigen-specific IgE antibodies captured from the circulation by mast cell 
processes extended across the vessel wall [7]. Binding of these antibodies with their 
respective antigen leads to crosslinking and subsequently aggregation of FcRIs thereby 
activating downstream signaling pathways and triggering the release of biologically 
active mediators [10]. In addition, mast cells can be activated via toll like receptors, G-
protein coupled receptors, various complement peptides and platelet activating factor, 
illustrating its crucial role in immune defense [3]. Of note, mast cells are armed with 
granules containing preformed and stored mediators, such as vasoactive amines like 
histamine, and proteases such as tryptases and chymases, enabling an immediate 
response. In addition, mast cells can synthesize and release lipid mediators such as 
prostaglandins and leukotriens within 1-2 hours after activation. Mast cells also release 
cytokines and chemokines, a process that typically occurs later and is associated with 
more chronic responses. The wide range of mediators released undoubtedly underlie 
the many different functions of mast cells and their involvement in a diversity of 
mechanisms, including secretion and epithelial permeability, immune cell recruitment 
and activation, blood flow, coagulation and vascular permeability, wound healing and 
fibrosis and neuro-immune interaction altering peristalsis, bronchoconstriction and 
pain [11]. 
 
Evidence in humans supporting a role for mast cells in IBD 
To date, only few studies have evaluated the potential involvement of mast cells in IBD, 
and most of them date back many years ago and are rather descriptive reporting on the 
number of mast cells. Gelbmann et al. [12] for example describe accumulation of mast 
cells particularly in hypertrophied and fibrotic muscularis propria in strictures of CD 
patients, suggesting an important role in the process of fibrosis. Others report on 
increased mast cells in the mucosa, submucosa, muscularis propria and surrounding fat 
in active CD [13]. More recently, increased mast cell numbers were counted in the colon 
of both CD and UC patients compared to controls [14] [15]. Activation of mast cells on 
the other hand is suggested by increased expression or release of mast cell mediators in 
the mucosa of IBD patients [16] [17] or by demonstration of increased levels of the N-
methylhistamine, one of the metabolites of histamine, in the urine of IBD patients 
compared to patients in remission and controls [18]. Although the above-mentioned 
observations may suggest a role for mast cells in IBD, this evidence is rather indirect and 
could also be secondary to the inflammatory response in the mucosa. The ultimate 
proof, i.e. clinical improvement by treatment with mast cell stabilizers or antagonist 
blocking the biological effect of mast cell mediators, is however currently lacking.  
 
Mast cells and colitis: preclinical data 
Several models of colitis are routinely used that can largely be divided in models of 
acute colitis[19], mostly due to exposure of the intestine to compounds damaging the 
intestinal barrier (dextran sulphate sodium (DSS)) in drinking water, enema of 
trinitrobenzene dissolved in alcohol) or more chronic models such as T cell transfer 
colitis or delayed-type hypersensitivity colitis (TNBS, dinitrofluoro-benzene). Clearly, 
the role of mast cells in colitis will largely depend on the type of model studied. Below, 
recent new data supporting a role for mast cells in colitis will be briefly summarized 
according to the type of colitis. 
 
Acute colitis 
Previous studies have yielded conflicting data regarding the role of mast cells in acute 
colitis [20]. Kurashima et al. however nicely demonstrated a pivotal role for ATP-
mediated activation of mast cells in DSS and TNBS colitis [15]. These authors 
demonstrated that treatment of mice with an antibody against the ATP receptor P2X7 
inhibits mast cell activation and subsequent intestinal inflammation. Moreover, mast 
cells expressing P2X7 purinoceptors in colons of mice with colitis and of patients with 
CD are increased in number. The most compelling evidence however is revealed by 
reconstitution experiments in mast cell deficient KitW-sh/W-sh mice. Intestinal 
inflammation triggered by DSS or TNBS in these mutant mice is ameliorated while 
reconstitution with wild type but not P2X7-/- mast cells results in susceptibility to 
develop colitis in response to DSS or TNBS [15]. Moreover, the authors showed 
increased ATP production in intestinal inflammation and demonstrated that ATP 
triggers MC activation through P2X7 purinoreceptors. Taken together, these data 
indicate that tissue damage induced by DSS or TNBS leads to ATP release subsequently 
activating MC by interacting with P2X7 receptors. These data reveal a role for MC in 
both the initiation and exacerbation of intestinal inflammation [15]. Of interest, the 
same group very recently showed that this pathway can be blocked by activation of the 
inhibitory receptor CD300f (also called leucocyte mono-immunoglobulin-like receptor 3 
or LMIR3) on mast cells by its ligand ceramide [21]. Mice deficient for LMIR3 developed 
more severe DSS colitis. Moreover, reconstitution of mast cell deficient mice with 
LMIR3-/- MC exhibited more severe colitis than mice that received wild type MC. 
Previously, the authors have shown that ceramide is a ligand of LIMR3 leading to 
inhibition of IgE-dependent MC activation [22]. In their recent paper, they take this 
finding further and show that ceramide-LIMR3 interaction not only inhibits ATP-
induced MC activation but also suppresses DSS colitis. These data are of great interest 
indicating LIMR3-targeted compounds such as ceramide as a novel therapeutic strategy 
for IBD [21]. 
In mice, mast cells store a variety of proteases on their secretory granules. These 
enzymes are of particular interest as they are involved in proteolytic processing of other 
molecules but can also act as signaling molecules by cleavage and activation of Protease-
activated receptors (PARs) [23]. The latter are abundantly expressed and trigger a wide 
array of pro-inflammatory processes upon activation, including colitis[24].  Two recent 
papers have studied the role of mast cell serine proteases in DSS colitis, in particular 
mouse MC protease-6 (mMCP-6), mMCP-7 and protease serine member S31 (Prss31) 
[25,26]. Hamilton et al. [25] elegantly showed that mMCP-6 null mice exposed to DSS 
had significantly less weight loss as well as lower pathological and endoscopical disease 
scores compared to mMCP-6 expressing mice. In line, the levels of the pro-inflammatory 
cytokines IL-6 and Il-1b and the chemokines CXCL1 and CXCL2, known to attract 
neutrophils, were significantly reduced in the mMCP-6 null mice. Of interest, similar 
findings were obtained in the TNBS colitis model. In a subsequent study, the same group 
showed that also Prss31 null mice lost less weight, had lower histopathological scores 
and contained less CXCL2 and IL-6 mRNA in their colons compared to WT mice 
following treatment with DSS. Taken together, these data provide strong evidence that 
both mMCP-6 and Prss31 contribute to the development of colitis and thus may 
represent interesting new targets for treatment of IBD [26].  
 
Delayed-type hypersensitivity colitis 
After sensitization, re-exposure to oxazolone, TNBS or dinitrofluorobenzene leads to a 
delayed-type of colitis. Classically, MC are activated by antigen mediated crosslinking of 
membrane bound IgE antibodies. Recently, Hoving et al. [27] provided evidence for IgE-
mediated activation of MC in oxazolone colitis. In vivo neutralization of IgE protected 
mice from oxazolone-induced colitis, a finding associated with a reduction in mast cell 
numbers and a reduction in the MC degranulation product MMCP-1 in serum. Moreover, 
mice that are unable to produce IgE were also protected against oxazolone-induced 
colitis. Next, the authors showed that IgE antibodies were produced by B cells in 
response to IL-13 released by CD4+ Th2 cells. Along the same line, Rijnierse et al. 
provided evidence that mast activation by immunoglobulin-free light chains (IgLCs) of 
immunoglobulins are involved in DNBS colitis [28]. Treatment of mice with the IgLC 
antagonist F991 prevented MC activation and abrogated the development of diarrhea, 
celllar infiltration and colonic lymphoid follicle hyperplasia. Passive immunization with 
antigen specific IgLCs and subsequent rectal challenge with the hapten elicited MC 
activation and increased vascular permeability in the colon of mice. Of note, serum 
concentrations of IgLCs in CD was increased while more IgLCs were detected in the 
ileum and colon of patients with IBD [28]. Based on the above, IgE dependent and IgE-
independent MC activation may be involved in IBD. Further data in human are however 
awaited. 
 
Stress, mast cells and IBD 
 A recent large prospective population-based study in 704 IBD patients identified 
perceived stress, negative affect or mood and major life events to be associated with 
symptomatic flares [29]. Knowing that stress is an important trigger of MC activation 
[30], MC could theoretically be involved in the triggering of these flares, perhaps by 
increasing permeability thereby exposing the immune system to increased levels of 
intraluminal antigens. Increased permeability has indeed been reported using biopsies 
of IBD patients [14] [31], whereas reactivation of colitis by stress was reported already 
many years ago. This effect was dependent on CD4+ T cells and increased permeability 
[32]. In 2009, evidence was reported suggesting that chronic psychological stress, 
through the release of substance P, triggers the expression and release of corticotrophin 
releasing hormone by eosinophils. This stress hormone then subsequently activates MC 
leading to epithelial barrier dysfunction [33].  The above-mentioned studies would 
suggest that stress-induced flares in IBD may at least partly be explained by MC-
mediated changes in barrier function and subsequent reactivation of the immune 
response. 
 
Summary and conclusion 
From the studies summarized above, MC seem to be involved both in the acute and more 
sustained inflammatory response, at least in preclinical models of IBD. As shown in 
Figure 1, MC can be activated by stress via eosinophil-derived CRH, IgLC, IgE or ATP 
leading to the release of a wide variety of mediators, including proteases, histamine, 
chemokines and cytokines, leading to the attraction of inflammatory cells, changes in 
barrier function, tissue remodeling etc. Increased permeability may contribute to 
increased influx of intraluminal antigens either activating MC or CD4+ T cells further 
contributing to the inflammatory response. This process can be antagonized by 
inhibition of MC activation via ceramide binding to the inhibitory receptor LIMR3. To 
what extent this also applies to IBD patients and to what extent MC are indeed a target 
for treatment remains to be proven. Clearly, the most convincing evidence will have to 
come from clinical studies evaluating new compounds in patients, however, data from 
randomized clinical trials are currently available. Nevertheless, based on the data 
summarized here, protease inhibitors[23,34] and ceramide[21] may represent 
interesting targets hopefully improving treatment of IBD patients.  
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Legend to Figure 1 
Schematic representation of the possible involvement of MC in IBD. For more detailed 
information, see main text. 
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